Presage Biosciences announced it has entered into a new research collaboration with Pure Biologics to evaluate two of Pure Biologics' very early stage assets in a Phase 0 intratumoral microdosing study. Presage's CIVO platform will be used to evaluate drug mechanism of action, potential indicators of efficacy, and drug combinations. The collaboration with Pure Biologics comes on the heels of Presage's recently completed Phase 0 clinical trials (NCT04065555 and NCT04541108) with Takeda Pharmaceutical Company evaluating immune-oncology drugs alone and in combination in head and neck cancer patients.

The trials demonstrated that CIVO is able to deliver key spatial biology and mechanistic insights. Presage expects to publish the results from both studies later this year.